Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
BCSD Portugal, 23 July 2021
Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.
Commitment to partnership and joint innovation for cell and gene therapies
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Irish Examiner, 21 june 2021
Hovione today announced an extension of collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field.
Google Chrome
Safari
Firefox
Edge